1. Search Result
Search Result
Results for "

central mechanism

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

5

Bibliotecas de Screening

1

Biochemical Assay Reagents

2

Peptides

4

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-113596
    Acetyl Coenzyme A trisodium
    4 Publications Verification

    Acetyl-CoA trisodium

    Oxidative Phosphorylation Endogenous Metabolite Autophagy Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) trisodium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trisodium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trisodium is also a key precursor of lipid synthesis .
    Acetyl Coenzyme A trisodium
  • HY-108652
    α,β-Methylene-ATP trisodium
    1 Publications Verification

    P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP trisodium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP trisodium
  • HY-B0061
    Tandospirone citrate
    3 Publications Verification

    SM-3997 citrate

    5-HT Receptor Neurological Disease Metabolic Disease
    Tandospirone (SM-3997) citrate is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone citrate has anxiolytic and antidepressant activities. Tandospirone citrate can be used for the research of the central nervous system disorders and the underlying mechanisms .
    Tandospirone citrate
  • HY-114293A

    Acetyl-CoA trilithium

    Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) trilithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trilithium regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trilithium is also a key precursor of lipid synthesis .
    Acetyl coenzyme A trilithium
  • HY-14558
    Tandospirone
    3 Publications Verification

    SM-3997

    5-HT Receptor Neurological Disease
    Tandospirone (SM-3997) is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms .
    Tandospirone
  • HY-114293

    Acetyl-CoA

    Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetyl coenzyme A
  • HY-P1248

    NPFF

    Neuropeptide FF Receptor Cardiovascular Disease Neurological Disease
    Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with Ki values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .
    Neuropeptide FF
  • HY-113596A
    Acetyl coenzyme A lithium
    4 Publications Verification

    Acetyl-CoA lithium

    Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis .
    Acetyl coenzyme A lithium
  • HY-114293S

    Acetyl-CoA-13C2 lithium

    Isotope-Labeled Compounds Endogenous Metabolite Autophagy Oxidative Phosphorylation Metabolic Disease
    Acetyl coenzyme A- 13C2 lithium is the 13C-labeled Acetyl coenzyme A (HY-114293). Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetyl coenzyme A-13C2 lithium
  • HY-134440A

    P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP
  • HY-114293S5

    Acetyl-CoA-d3

    Isotope-Labeled Compounds Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl coenzyme A-d3 (Acetyl-CoA-d3) is the deuterium labeled Acetyl coenzyme A (HY-114293). Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetyl coenzyme A-d3
  • HY-14790

    (S,S)-(+)-Reboxetine

    Adrenergic Receptor Neurological Disease
    Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine reuptake inhibitor with activity in increasing urethral resistance. Esreboxetine has been reported to be effective in patients with stress urinary incontinence in a Phase IIa clinical study, achieving this effect by increasing urethral closure. The mechanism of action of esreboxetine involves inhibition of norepinephrine transporters in the central and peripheral nervous systems. The peripheral selectivity of esreboxetine helps it significantly increase urethral resistance without penetrating the brain .
    Esreboxetine
  • HY-P3548

    Opioid Receptor Neurological Disease
    [D-Ala2]-Met-Enkephalinamide, an opioid peptide, is a potent opioid agonist. [D-Ala2]-Met-Enkephalinamide decreases bile flow by a central mechanism. [D-Ala2]-Met-Enkephalinamide has analgesic properties .
    [D-Ala2]-Met-Enkephalinamide
  • HY-110053

    SM-3997 hydrochloride

    5-HT Receptor Neurological Disease
    Tandospirone (SM-3997) hydrochloride is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone hydrochloride has anxiolytic and antidepressant activities. Tandospirone hydrochloride can be used for the research of the central nervous system disorders and the underlying mechanisms .
    Tandospirone hydrochloride
  • HY-155297

    FLA-136

    Histamine Receptor Cardiovascular Disease
    Nebidrazine is a centrally-acting hypotensive agent compared to clonidine, demonstrating weaker cardiovascular effects in rats. It induces dose-dependent hypotension and bradycardia when administered intracerebroventricularly (i.c.v.), with significantly lower sedative potential than clonidine in conscious rats. Yohimbine attenuates the cardiovascular effects of both Nebidrazine and clonidine, suggesting involvement of central alpha-autoreceptors sensitive to yohimbine. Unlike clonidine, Nebidrazine does not affect peripheral alpha-adrenoceptors in pithed rats, indicating a selective central mechanism. Chemical sympathectomy reduces Nebidrazine's cardiovascular effects more than clonidine's, and metiamide diminishes responses to both drugs, implicating central histamine receptors. These findings highlight Nebidrazine's distinct pharmacological profile and potential therapeutic application in managing hypertension through central alpha-autoreceptor stimulation .
    Nebidrazine
  • HY-134440

    P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP dilithium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP dilithium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP dilithium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP dilithium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP dilithium
  • HY-W747554

    nAChR Neurological Disease
    SM 32 is an analgesic. SM 32 produces an increase in ACh release. SM 32 amplifies electrically- and nicotine- evoked guinea-pig ileum contractions. SM32 induces antinociceptive effects through a central cholinergic mechanism .
    SM 32
  • HY-113833

    Adrenergic Receptor Endocrinology
    N-Methylindan-2-amine hydrochloride (compound 3b) is an N-alkylated congener of phenylethylamine that increases hot plate reaction time in mice without inducing dopaminergic effects. N-Methylindan-2-amine hydrochloride can be used to study central noradrenergic mechanisms .
    N-Methylindan-2-amine hydrochloride
  • HY-14558R

    SM-3997 (Standard)

    Reference Standards 5-HT Receptor Neurological Disease
    Tandospirone (Standard) is the analytical standard of Tandospirone. This product is intended for research and analytical applications. Tandospirone (SM-3997) is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms .
    Tandospirone (Standard)
  • HY-14558S

    SM-3997-d8

    Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    Tandospirone-d8 (SM-3997-d8) is deuterium labeled Tandospirone. Tandospirone (SM-3997) is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms .
    Tandospirone-d8
  • HY-E70262

    Oxidative Phosphorylation Endogenous Metabolite Metabolic Disease
    Acetoyl-CoA (triammonium) is a triammonium derivative of Acetoyl-CoA (HY-114293), Acetyl-CoA is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetoyl-CoA triammonium
  • HY-137055

    Others Others
    PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
    PF-3774076
  • HY-P2782A

    Endogenous Metabolite Metabolic Disease
    Chloramphenicol Acetyltransferase, Escherichia coli is a bacterial enzyme that detoxifies the antibiotic chloramphenicol and is responsible for chloramphenicol resistance in bacteria. Chloramphenicol Acetyltransferase, Escherichia coli covalently attaches an acetyl group from acetyl-CoA to chloramphenicol, which prevents chloramphenicol from binding to ribosomes. A histidine residue, located in the C-terminal section of Chloramphenicol Acetyltransferase, Escherichia coli, plays a central role in its catalytic mechanism.
    Chloramphenicol Acetyltransferase, Escherichia coli
  • HY-108652R

    Reference Standards P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP trisodium (Standard) is the analytical standard of α,β-Methylene-ATP (trisodium) (HY-108652). This product is intended for research and analytical applications. α,β-Methylene-ATP trisodium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP trisodium (Standard)
  • HY-101196

    Endogenous Metabolite Neurological Disease
    PG 9 maleate is a compound with analgesic and anti-memory loss activity. PG 9 maleate exerts analgesic effects by enhancing central cholinergic transmission. PG 9 maleate protects against memory loss caused by scopolamine or dicyclomine within a specific dose range. The affinity profile of PG 9 maleate indicates significant selectivity among the M4/M1 receptor subtypes, which may be the mechanism for its analgesic and anti-memory loss effects. PG 9 maleate can increase the release of acetylcholine, thereby improving its biological activity .
    PG 9 maleate
  • HY-N18471

    5,7-DHP

    Monoamine Oxidase 5-HT Receptor Cardiovascular Disease Neurological Disease
    5,7-Dihydroxytryptamine (5,7-DHP) is an autofluorescent (λex≈365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
    5,7-Dihydroxytryptamine
  • HY-N18471A

    5,7-DHP hydrobromide

    Monoamine Oxidase 5-HT Receptor Neurological Disease
    5,7-Dihydroxytryptamine (5,7-DHT) hydrobromide is an autofluorescent (Ex ≈ 365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine hydrobromide can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine hydrobromide can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
    5,7-Dihydroxytryptamine hydrobromide
  • HY-N18471B

    5,7-DHP creatinine sulfate

    Monoamine Oxidase 5-HT Receptor Cardiovascular Disease Neurological Disease
    5,7-Dihydroxytryptamine creatinine sulfate (5,7-DHT) is an autofluorescent (Ex ≈ 365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine creatinine sulfate can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine creatinine sulfate can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
    5,7-Dihydroxytryptamine creatinine sulfate

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

 

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

 

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: